Search results for " Lobular"

showing 10 items of 22 documents

Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.

2021

Primary triple-negative invasive lobular breast carcinomas (TN-ILCs), which do not express hormone receptors and HER2 at diagnosis, are rare and poorly known. In this study, we analyzed the largest TN-ILC series ever reported in the literature, in comparison to phenotypically similar breast tumor subtypes: triple-negative invasive ductal carcinoma (TN-IDC) and hormone receptor-positive invasive lobular carcinoma (HR + ILC). All primary TN-ILCs registered in our database between 2000 and 2018 (n = 38) were compared to tumors from control groups, matched by stage and Elston/Ellis grade, with regard to clinical, pathologic, and immunohistochemical characteristics. A comparative molecular analy…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPathologyReceptor ErbB-2Lobular carcinomaDNA Mutational AnalysisTriple Negative Breast NeoplasmsArticlePathology and Forensic Medicine03 medical and health sciencesBasal (phylogenetics)Phosphatidylinositol 3-Kinases0302 clinical medicineBreast cancerInternal medicinemedicineCarcinomaHumansskin and connective tissue diseasesSurvival analysisAgedAged 80 and overbusiness.industryMiddle Agedmedicine.diseaseAndrogen receptorbody regionsCarcinoma Lobular030104 developmental biologyPleomorphism (cytology)Receptors EstrogenReceptors Androgen030220 oncology & carcinogenesisInvasive lobular carcinomaMutationFemalebusinessModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
researchProduct

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)

2021

Abstract Background The GAIN-2 trial was designed to identify a superior intense dose-dense (idd) strategy for high-risk patients with early breast cancer. Here, we report an interim analysis, at which the predefined futility boundary was crossed. Patients and methods GAIN-2 was an open-label, randomised, multicentre phase III trial. Two thousand eight hundred and eighty seven patients were randomised 1:1 between three courses each of idd epirubicin (E) 150 mg/m2, nab-paclitaxel (nP) 330 mg/m2 and cyclophosphamide (C) 2000 mg/m2 (iddEnPC) versus four cycles of leucocyte nadir-based tailored and dose-dense EC (dtEC) followed by four cycles of tailored and dose-dense docetaxel (dtD) (dtEC-dtD…

AdultCancer Researchmedicine.medical_specialtyTime FactorsAdolescentPaclitaxelCyclophosphamideDose-dense chemotherapymedicine.medical_treatmentBreast NeoplasmsDocetaxelRisk AssessmentDisease-Free SurvivalYoung AdultRisk FactorsAlbuminsGermanyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAdverse effectCyclophosphamideAgedEpirubicinChemotherapybusiness.industryCarcinoma Ductal BreastCancerMiddle AgedInterim analysismedicine.diseaseNeoadjuvant TherapyCarcinoma LobularCarcinoma Intraductal NoninfiltratingOncologyDocetaxelChemotherapy AdjuvantFemalebusinessmedicine.drugEpirubicinEuropean Journal of Cancer
researchProduct

The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma

2016

The prognostic value of sentinel lymph node micrometastases in invasive breast cancer patients is still widely debated. Even if, in the absence of unequivocal guidelines, the axillary lynphadenectomy is not still performed in the routine clinical care of these patients.We have retrospectively analyzed 746 patients with operable invasive breast cancer and clinically negative axillary lymph nodes. These patients underwent conservative surgery or total mastectomy with sentinel lymph node biopsy. Patients with micrometastases in the sentinel lymph node treated with axillary dissection has been checked and the involvement of the remaining lymph nodes analyzed. Patients with micrometastases in th…

AdultNeoplasms Hormone-DependentBiopsy Fine-NeedleBreast carcinomaBreast NeoplasmsHumansRadionuclide ImagingTechnetium Tc 99m Aggregated AlbuminMastectomyAgedRetrospective StudiesAged 80 and overSentinel Lymph Node BiopsyCarcinoma Ductal BreastMicrometaseMiddle AgedPrognosisCombined Modality TherapyCarcinoma LobularNeoplasm MicrometastasisLymphatic MetastasisBreast carcinoma; Micrometases; Sentinel lymph node; SurgeryAxillaLymph Node ExcisionFemaleSurgeryNeoplasm Recurrence LocalRadiopharmaceuticalsSentinel lymph node
researchProduct

p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer

2006

AbstractBackground: The HER-2 receptor undergoes a proteolytic cleavage generating an NH2-terminally truncated fragment, p95HER-2, that is membrane-associated and tyrosine-phosphorylated. We have reported that p95HER-2, but not the full-length receptor, p185HER-2, correlated with the extent of lymph node involvement in patients with breast cancer and its expression was significantly enhanced in nodal metastatic tissue. These facts suggested an important role for p95HER-2 either as a marker or cause of metastasis and poor outcome in breast cancer. In this work, we have studied the prognostic value of p95HER-2 in breast cancer.Methods: Primary breast tumor tissues (n = 483) were from surgical…

AdultOncologyCancer ResearchPathologymedicine.medical_specialtyReceptor ErbB-2Breast NeoplasmsMetastasisBreast cancerRisk FactorsInternal medicineBiomarkers TumorTumor Cells CulturedmedicineCarcinomaHumansLymph nodeSurvival rateAgedAged 80 and overbusiness.industryCarcinoma Ductal BreastHazard ratioMiddle AgedPrognosismedicine.diseasePrimary tumorConfidence intervalSurvival RateCarcinoma Lobularmedicine.anatomical_structureReceptors EstrogenOncologyLymphatic MetastasisFemaleLymph NodesReceptors ProgesteronebusinessClinical Cancer Research
researchProduct

Autoantibodies in breast cancer: their use as an aid to early diagnosis

2007

There is increasing evidence that the immune system produces a humoral response to cancer-derived antigens. This study assessed the diagnostic potential of autoantibodies to multiple known tumour-associated proteins.Sera from normal controls (n = 94), primary breast cancer patients (n = 97) and patients with ductal carcinoma in situ (DCIS) (n = 40) were investigated for the presence of autoantibodies to p53, c-myc, HER2, NY-ESO-1, BRCA1, BRCA2 and MUC1 antigens by enzyme-linked immunosorbent assay.Reproducibly elevated levels of autoantibodies were seen in at least one of the six antigens in 64% of primary breast cancer patient sera and 45% of patients with DCIS at a specificity of 85%. No …

AdultOncologyPathologymedicine.medical_specialtyAntibodies NeoplasmBreast NeoplasmsEnzyme-Linked Immunosorbent Assaymedicine.disease_causeSensitivity and SpecificityAutoimmunityCohort StudiesBreast cancerAntigenAntigens NeoplasmInternal medicinemedicineHumansMammographyNeoplasm Metastasisskin and connective tissue diseasesLymph nodeAgedAutoantibodiesAged 80 and overmedicine.diagnostic_testbusiness.industryAutoantibodyReproducibility of ResultsCancerHematologyMiddle Agedmedicine.diseaseCarcinoma LobularCarcinoma Intraductal NoninfiltratingEarly Diagnosismedicine.anatomical_structureIncreased riskReceptors EstrogenOncologyCase-Control StudiesFemalebusinessAnnals of Oncology
researchProduct

Imunohistochemical Demonstration of Carcinoembryonic Antigen (CEA) in 120 Mammary Carcinomas and its Correlation with Tumor Type, Grading, Staging Pl…

1985

Antisera to CEA were used for the immunohistochemical localization and quantification of this antigen in 120 Bouin-fixed, paraffin embedded mammary carcinomas. These results were compared to tumor type, grading, staging, biochemical receptor status, cytosolic CEA-levels of the same tumors, and preoperative plasma CEA-levels. Mammary carcinomas were usually characterized by a low percentage of CEA-positive tumor cells: 50.9% of the cases contained more than 5% CEA-positive tumor cells and were therefore defined as being CEA-histopositive in this study. A relation could be shown between CEA-histopositivity and the histologic tumor type. The majority of invasive lobular carcinomas, tubular, an…

AdultPathologymedicine.medical_specialtyReceptor Statusendocrine system diseasesBreast NeoplasmsPathology and Forensic MedicineImmunoenzyme TechniquesCarcinoembryonic antigenAntigenAntigens NeoplasmmedicineCarcinomaHumansneoplasmsEstrogen Receptor StatusGrading (tumors)Agedbiologybusiness.industryCarcinomaCell BiologyMiddle Agedmedicine.diseasedigestive system diseasesCarcinoembryonic AntigenCarcinoma Intraductal NoninfiltratingReceptors EstrogenInvasive lobular carcinomabiology.proteinImmunohistochemistryFemalebusinessPathology - Research and Practice
researchProduct

The accuracy of sentinel lymph node biopsy in the treatment of multicentric invasive breast cancer using a subareolar injection of tracer.

2008

BACKGROUND: The aim of this study was to evaluate the feasibility and the accuracy of sentinel lymph node biopsy in multicentric breast cancer (MBC) performed by means of a subareolar (SA) injection of both 99Tc-labeled human albumin colloid and lymphazurin. METHODS: Between January 2002 and October 2007, 34 patients with MBC with clinically negative axilla underwent sentinel lymph node biopsy (SLNB) followed by total axillary node dissection (AD). Overall successful identification rate of SLN was 100%; there were no false negatives and overall accuracy rate was 100%. RESULTS: The mean number of sentinel lymph nodes (SLNs) identified was 1.8 +/- 0.88 (range = 1-4); the mean number of axilla…

Adultmedicine.medical_specialtyAxillary lymph nodesInjections IntradermalSentinel lymph nodeBreast NeoplasmsIsosulfan BlueSettore MED/08 - Anatomia PatologicaCohort StudiesBreast cancerPredictive Value of TestsBiopsymedicineRosaniline DyesHumansRadioactive TracersColoring AgentsTechnetium Tc 99m Aggregated AlbuminAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industrySentinel Lymph Node BiopsyCarcinoma Ductal BreastReproducibility of ResultsSentinel Lymph Node Biopsy Multicentric Invasive Breast CancerMiddle Agedmedicine.diseaseSurgeryAxillaCarcinoma LobularSettore MED/18 - Chirurgia Generalemedicine.anatomical_structureSurgeryFemaleBreast diseaseRadiologyLymphRadiopharmaceuticalsbusiness
researchProduct

The value of intraoperative frozen section examination of sentinel lymph nodes in surgical management of breast carcinoma.

2009

PURPOSE: In breast cancer staging, the need for intraoperative sentinel lymph node (SLN) evaluation has still not been adequately established. This study investigates the impact of intraoperative frozen section (FS) evaluation of SLN to avoid subsequent axillary lymph node dissection (ALND) in patients with positive SLN. METHODS: A retrospective review of 364 breast cancer patients undergoing SLN biopsy with intraoperative FS evaluation of SLN was performed. RESULTS: Sensitivity and accuracy of FS examination of SLN were 76.4% and 94.2%, respectively. The sensitivity was significantly higher in larger tumors (p < 0.01). No significant correlation was found between FS and histologic type. A …

Adultmedicine.medical_specialtyBreast surgerymedicine.medical_treatmentSentinel lymph nodeBreast NeoplasmsSettore MED/08 - Anatomia PatologicaSensitivity and SpecificityIntraoperative PeriodBreast cancermedicineFrozen SectionsHumansBreastSentinel lymph node - Frozen section - Intraoperative - Breast carcinomaLymph nodeMastectomyAgedNeoplasm StagingRetrospective StudiesAged 80 and overbusiness.industrySentinel Lymph Node BiopsyGeneral surgeryCarcinoma Ductal BreastAxillary Lymph Node DissectionReproducibility of ResultsMiddle Agedmedicine.diseaseCarcinoma LobularSettore MED/18 - Chirurgia Generalemedicine.anatomical_structureLymphatic MetastasisAxillaLymph Node ExcisionSurgeryFemaleIntraoperative PeriodRadiologyLymph NodesbusinessBreast carcinomaMastectomy
researchProduct

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

2014

Introduction More than 70 common alleles are known to be involved in breast cancer (BC) susceptibility, and several exhibit significant heterogeneity in their associations with different BC subtypes. Although there are differences in the association patterns between BRCA1 and BRCA2 mutation carriers and the general population for several loci, no study has comprehensively evaluated the associations of all known BC susceptibility alleles with risk of BC subtypes in BRCA1 and BRCA2 carriers. Methods We used data from 15,252 BRCA1 and 8,211 BRCA2 carriers to analyze the associations between approximately 200,000 genetic variants on the iCOGS array and risk of BC subtypes defined by estrogen re…

Cancer ResearchReceptor ErbB-2Genes BRCA2BRCALOCIGenes BRCA1MODIFIERSVARIANTSErbB-2610 Medical sciences MedicineDuctalReceptorsMedicine and Health SciencesINVESTIGATORSBreastskin and connective tissue diseasesProgesteroneMedicine(all)Carcinoma Ductal BreastMiddle AgedAdult; Aged; Alleles; Breast Neoplasms; Carcinoma; Carcinoma Ductal Breast; Carcinoma Lobular; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Receptor ErbB-2; Receptors Estrogen; Receptors Progesterone; Genes BRCA1; Genes BRCA2; Cancer Research; OncologyOncologyReceptors EstrogenTUMOR SUBTYPESFemaleReceptors ProgesteroneReceptorResearch ArticleAdultHeterozygote610Breast NeoplasmsMEDULLARY CARCINOMAOVARIAN-CANCERLobularHumansGenetic Predisposition to DiseaseGENOME-WIDE ASSOCIATIONAllelesAgedNeoplasm StagingAdult; Aged; Alleles; Breast Neoplasms; Carcinoma; Carcinoma Ductal Breast; Carcinoma Lobular; Female; Genetic Predisposition to Disease; Heterozygote; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Receptor ErbB-2; Receptors Estrogen; Receptors Progesterone; Genes BRCA1; Genes BRCA2CONSORTIUMCarcinomaBRCA1EstrogenBRCA2Carcinoma LobularESTROGEN-RECEPTORGenesNeoplasm GradingBreast Cancer Research
researchProduct

Underestimation of atypical lobular hyperplasia and lobular carcinoma in situ at stereotaxic 11-gauge vacuum-assisted breast biopsy

2013

The aims of this study are to determine the frequency of diagnosis of atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) at stereotaxic-guided 11-gauge vacuum-assisted breast biopsy (VABB) and to assess the rate of underestimation of these at subsequent surgical excision and follow-up. Moreover, we aimed to define clinical, radiological and histological features of nonpalpable lesions in core biopsies that predict the lesion upgrade. Retrospective review of 11-gauge VABB was performed to identify the underestimation rate of nonpalpable lesions diagnosed as ALH or LCIS at VABB. Thirteen cases of ALH and 36 cases of LCIS were sent to surgery, 29 cases of ALH and 14 cases…

In situPathologymedicine.medical_specialtymedicine.diagnostic_testbusiness.industryImmunologyLobular carcinomalcsh:RAtypical lobular hyperplasialcsh:Medicinemedicine.diseaseBiopsyVacuum-assisted breast biopsyImmunology and AllergyMedicinebusinessLobular Neoplasia
researchProduct